Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for use by hospitals.
Clinical Benefit
| Substantial |
The actual benefit of RANEXA in this indication is substantial. |
Clinical Added Value
| no clinical added value |
RANEXA should be used only by patients with stable angina that is inadequately controlled or who are intolerant to betablockers and/or calcium channel blockers.
Given the data available, RANEXA does not provide any improvement in actual benefit (IABV) in the management of these patients. |
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
dnXFULFFwkCMaE1s
